PPARD and metabolic disease: Li et al. designed some hybrid compounds of AM-4668, CP-1 (FFA1 agonist), and GW501516 (selective PPARδ agonist) as dual agonists of FFA1 and PPARδ in the treatment of several metabolic disorders.